What do systematic reviews say?

Intervention not reported

The intervention probably leads to higher failure of first‐line therapy (moderate certainty).

• First‐line chemotherapy in low‐risk gestational trophoblastic neoplasia 2016 · Cochrane Headline outcomes only
  RR 3.55 [1.81, 6.95]
  6 studies · 577 participants
  Moderate

mTOR inhibitors vs chemotherapy/hormone therapy

mTOR inhibitors may leads to higher progression‐free survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).

• PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
  HR 1.43 [1.06, 1.93]
  1 study · 231 participants
  Low

mTOR inhibitors vs chemotherapy/hormone therapy

mTOR inhibitors showed no clear difference in overall survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).

• PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
  HR 1.32 [0.98, 1.78]
  1 study · 231 participants
  Low

mTOR inhibitors vs chemotherapy/hormone therapy

mTOR inhibitors showed no clear difference in objective response rate: first‐line trial compared with chemotherapy/hormone therapy (low certainty).

• PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
  RR 0.93 [0.75, 1.17]
  1 study · 231 participants
  Low

EGFR tyrosine kinase inhibitor (TKI) vs observation

EGFR tyrosine kinase inhibitor (TKI) showed no clear difference in overall survival compared with observation alone (low certainty).

• Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
  HR 0.99 [0.81, 1.2]
  1 study · 835 participants
  Low

EGFR tyrosine kinase inhibitor (TKI) vs observation

It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) changes progression‐free survival compared with observation alone (very low certainty).

• Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
  HR 1.05 [0.9, 1.23]
  1 study · 835 participants
  Very low

EGFR tyrosine kinase inhibitor (TKI) vs observation

• Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 835 participants
  Very low

Intervention not reported

The intervention probably leads to lower primary cure (remission) (moderate certainty).

• First‐line chemotherapy in low‐risk gestational trophoblastic neoplasia 2016 · Cochrane Headline outcomes only
  RR 0.65 [0.57, 0.75]
  6 studies · 577 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in severe adverse events (≥ grade 3) (low certainty).

• First‐line chemotherapy in low‐risk gestational trophoblastic neoplasia 2016 · Cochrane Headline outcomes only
  RR 0.35 [0.08, 1.66]
  5 studies · 515 participants
  Low

Intervention not reported

The intervention showed no clear difference in nausea (moderate certainty).

• First‐line chemotherapy in low‐risk gestational trophoblastic neoplasia 2016 · Cochrane Headline outcomes only
  RR 0.61 [0.29, 1.26]
  4 studies · 466 participants
  Moderate

Intervention not reported

• First‐line chemotherapy in low‐risk gestational trophoblastic neoplasia 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low